No Data
No Data
Dong-E-E-Jiao Co.,Ltd. (SZSE:000423) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Dong-e-e-jiao (000423.SZ): It is expected that donkey hide prices will rise in the near future.
Dong-E-E-Jiao (000423.SZ) stated during an investor relations event that currently, donkey hide prices remain relatively stable. In the future, there is an expected upward trend in donkey hide prices. The company will continue to optimize the donkey hide raw material supply guarantee mechanism, take multiple measures through lean management, optimizing product structure, etc., to ensure the supply of donkey hide raw materials.
Dong-E-E-Jiao (000423.SZ): Medical insurance-related policies have not had a significant adverse effect on the development of compound E-Jiao syrup products.
On August 2nd, Gelunhui reported that Dong-e-e-jiao (000423.SZ) stated in the investor relations event that in recent years, the company has focused on the construction of the entire industry chain and fully launched a global strategy for the development of major varieties, resulting in significant growth in product sales, particularly in the exclusive product of compound gelatinous syrup for replenishing qi and blood. Regarding changes in medical insurance policies and other situations, the company has conducted comprehensive research and judgement in a timely manner and responded comprehensively by tracking the changes dynamically. At present, it seems that the medical insurance-related policies have not had a significant adverse impact on the development of compound gelatinous syrup. In the future, the company will continue to focus on consumer demand, focus on the efficacy of compound gelatinous syrup products, and start from the perspective of pharmacoeconomics.
China Renaissance Starts Dong-E-E-Jiao at Buy With 83.78 Yuan Price Target
Dong-E-E-Jiao Co.,Ltd.'s (SZSE:000423) Last Week's 4.3% Decline Must Have Disappointed Retail Investors Who Have a Significant Stake
CICC: Maintains an outperform rating on Chinares Pharma with a target price of HKD 7.3.
CICC released a research report stating that Chinares Pharma (03320) was maintaining its rating of "outperform the industry," with EPS forecasts of $0.69/$0.77 for 2024/2025 remaining unchanged, corresponding to a year-on-year increase of 12.0%/12.2%, with a target price of HK$7.3. On July 17th, the company announced that its subsidiary, China Resources Boya Bio-Pharmaceutical Group, intends to acquire 100% equity of Lvxing Hong Kong Holdings for 1.82 billion yuan. On July 11th, Dong-E-E-Jiao, a subsidiary of the company, released its performance forecast for the first half of 2024, with preliminary estimates of net income attributable to shareholders at 0.695-0.76 billion yuan, a year-on-year increase of 31-43%. CICC's main points of view are as follows:
No Data